drug · small molecule
LIDOCAINE
Marketedupdated 3mo agoby MEDRx Co Ltd🔗 ChEMBL
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 8- tagApproval330 co-mentions · 137 sources
- druglidocaine SR278 co-mentions · 174 sources
- drugLIDOCAINE HYDROCHLORIDE AND EPINEPHRINE238 co-mentions · 81 sources
- drugLIDOCAINE HYDROCHLORIDE236 co-mentions · 140 sources
- drugAKTEN228 co-mentions · 139 sources
- drugLinisol223 co-mentions · 139 sources
- drugLaryng-O-Jet223 co-mentions · 139 sources
- drugLIDOCAINE HYDROCHLORIDE 0.4% IN DEXTROSE 5%223 co-mentions · 139 sources
Small molecule drug with a maximum clinical stage of Approval (across all indications), with 21 approved and 110 investigational indications.
targets
Sodium channel alpha subunit
all catalysts(5)
phase 2 completion · 3
Apr 27, 2026
phase 2 completion
Sustained Therapeutics Inc — lidocaine SR (Phase II Trial Completion)
LIDOCAINE
→
Apr 30, 2026
phase 2 completion
Huadong Hospital Affiliated to Fudan University — lidocaine (Phase II Trial Completion)
LIDOCAINE
→
Apr 30, 2026
phase 2 completion
Cairo University — lidocaine (Phase II Trial Completion)
LIDOCAINE
→
Trials studying LIDOCAINE
- N/AEfficacy and Safety of Rejuviel V in the Correction of Midface Volume Deficit
- phase1Bioequivalence Study of Lidocaine and Prilocaine Cream in Healthy Chinese Subjects
- phase4Workflow Optimization During Pulse Field Ablation for Atrial Fibrillation
- phase3Saypha® VOLUME Lidocaine for Midface Augmentation
- phase4Study Evaluating the Efficacy and Safety of Chloroprocaine HCl Ophthalmic Gel 3% vs Proparacaine Ophthalmic Solution 0.5% Plus Subconjunctival Lidocaine in Patients Undergoing Intravitreal Injections
- phase3Efficacy and Safety of Intravenous Lidocaine Versus Placebo in Patients Receiving Morphine-rachi Analgesia
- phase2A Randomized, Controlled Study of Repeat Dose Sustained Release Lidocaine for Treatment of Chronic Scrotal Pain
- —Prospective, Non-interventional Study Assessing Periorbital Rejuvenation Procedure
Patent cliff
source: FDA Orange Bookfirst barrier falls
Sep 24, 2028
~2.1 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (8)
- May 10, 2031formulationUS 107656404.7y
- May 10, 2031formulationUS 107657494.7y
- May 10, 2031formulationUS 112786234.7y
- May 10, 2031formulationUS 117864554.7y
- May 10, 2031method-of-use (U-2267)US 117937664.7y
- May 10, 2031formulationUS 92831744.7y
- May 10, 2031formulationUS 99252644.7y
- May 10, 2031formulationUS 99314034.7y
FDA exclusivities (1)
- Sep 24, 2028NPNP2.1y
News(3)
- Convenience Kit Correction: Medline Issues Correction for Kits Containing Huons Lidocaine Hydrochloride and Bupivacaine Hydrochloride in Dextrose InjectionMedline is correcting affected convenience kits by removing recalled Lidocaine Hydrochloride and Bupivacaine Hydrochloride in Dextrose Injection components from affected convenience kits.fda_medwatch · 8d ago
- Convenience Kit Correction: Argon Medical Issues Correction for Convenience Kits Containing Spectra Medical Device Lidocaine AmpulesArgon Medical is correcting affected convenience kits by removing included Spectra Medical Devices Lidocaine Ampules.fda_medwatch · 12d ago
- Convenience Kit Correction: Arrow International Issues Correction for Convenience Kits Containing Recalled Huons Lidocaine and Bupivacaine and SalineSaline, Lidocaine and Bupivacaine from affected convenience kits should not be used.fda_medwatch · 26d ago
Data sources
last refreshed 17m ago
Found something off?
comments(0)
5-min edit window · permanent after that